Aura Biosciences (AURA) Capital Expenditures (2020 - 2026)
Aura Biosciences' (AURA) quarterly Capital Expenditures came in at $46000.0 in Q1 2026, down 73.86% on a QoQ basis from $176000.0 in Q4 2025.
Aura Biosciences (AURA) Capital Expenditures (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Capital Expenditures data on file, last reported at $46000.0 in Q1 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $46000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $493000.0 (down 56.41% YoY) and the FY2025 annual result came in at $447000.0, down 64.33% from the prior year.
- Capital Expenditures eased to $46000.0 in Q1 2026, from $176000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.7 million in Q4 2024 to a low of -$556000.0 in Q4 2022.
- A 5-year average of $126250.0 and a median of $112000.0 in 2022 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 1135.12% in 2024, down 269.08% in 2024.
- Tracing AURA's Capital Expenditures over 5 years: stood at -$556000.0 in 2022, then jumped by 69.78% to -$168000.0 in 2023, then soared by 1135.12% to $1.7 million in 2024, then sank by 89.88% to $176000.0 in 2025, then sank by 73.86% to $46000.0 in 2026.
- The last three Capital Expenditures figures came in at $46000.0 (Q1 2026), $176000.0 (Q4 2025), and $45000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | 566,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 566,000.00 |
| Jun 30, 2026 | 566,000.00 |
| Mar 31, 2026 | 46,000.00 |
| Mar 31, 2026 | 46,000.00 |
| Dec 31, 2025 | 176,000.00 |
| Dec 31, 2025 | 176,000.00 |
| Sep 30, 2025 | 45,000.00 |
| Sep 30, 2025 | 45,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Dec 31, 2024 | 1.74 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | -421,000.00 |
| Sep 30, 2024 | -421,000.00 |
| Jun 30, 2024 | -187,000.00 |
| Jun 30, 2024 | -187,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | -168,000.00 |
| Dec 31, 2023 | -168,000.00 |